CXCL8 and asthma: Although current guidelines recommend both tezepelumab and dupilumab for severe asthma, particularly eosinophilic asthma with elevated blood eosinophil counts or FeNO levels [1], our findings suggest that dupilumab may provide greater benefits than tezepelumab in virus-induced asthma exacerbations, where excessive IL-8 production occurs, as tezepelumab does not inhibit this pathway [57].